{"nctId":"NCT01640951","briefTitle":"4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis","startDateStruct":{"date":"2012-09-16","type":"ACTUAL"},"conditions":["Moderate to Severe Chronic Plaque-Type Psoriasis"],"count":675,"armGroups":[{"label":"AIN457 150 mg - Fixed Interval (FI)","type":"EXPERIMENTAL","interventionNames":["Drug: AIN457 150 mg","Drug: Placebo"]},{"label":"AIN457 150 mg - Start of relapse (SoR)","type":"EXPERIMENTAL","interventionNames":["Drug: AIN457 150 mg","Drug: Placebo"]},{"label":"AIN457 300 mg - Fixed Interval (FI)","type":"EXPERIMENTAL","interventionNames":["Drug: AIN457 300 mg"]},{"label":"AIN457 300 mg - Start of Relapse (SoR)","type":"EXPERIMENTAL","interventionNames":["Drug: AIN457 300 mg","Drug: Placebo"]},{"label":"AIN457 300 mg - Open Label (OL)","type":"EXPERIMENTAL","interventionNames":["Drug: AIN457 300 mg"]}],"interventions":[{"name":"AIN457 150 mg","otherNames":["Secukinumab 150 mg"]},{"name":"AIN457 300 mg","otherNames":["Secukinumab 300 mg"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed consent according to local laws and regulations.\n2. Subjects who complete Week 52 of study CAIN457A2304 or complete Week 40 of study CAIN457A2307\n3. Subjects expected to benefit from participation in the extension study, as assessed by the subject and investigator\n\nExclusion Criteria:\n\n1. A protocol deviation in the core studies which according to the investigator will prevent the meaningful analysis of the extension study for the individual subject\n2. Ongoing use of prohibited psoriasis or non-psoriasis treatments. Time period from last use of prohibited treatments in the core study to first dose of study drug in this extension study.\n3. Subjects expected to be exposed to an undue safety risk if participating in the trial\n4. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial\n5. Plans for administration of live vaccines during the study period\n6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\\>10 mIU/mL).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Long-term Safety and Tolerability of Secukinumab","description":"Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"92.0","spread":null},{"groupId":"OG002","value":"92.9","spread":null},{"groupId":"OG003","value":"78.2","spread":null},{"groupId":"OG004","value":"87.4","spread":null},{"groupId":"OG005","value":"80.0","spread":null},{"groupId":"OG006","value":"94.6","spread":null},{"groupId":"OG007","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"24.0","spread":null},{"groupId":"OG002","value":"23.8","spread":null},{"groupId":"OG003","value":"16.4","spread":null},{"groupId":"OG004","value":"20.0","spread":null},{"groupId":"OG005","value":"18.3","spread":null},{"groupId":"OG006","value":"17.0","spread":null},{"groupId":"OG007","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"0.6","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"0.0","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"0.0","spread":null},{"groupId":"OG007","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Score of 75 at Weeks 52, 104, 156, 208 and 260","description":"PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"65.3","spread":null},{"groupId":"OG002","value":"67.5","spread":null},{"groupId":"OG003","value":"88.9","spread":null},{"groupId":"OG004","value":"38.2","spread":null},{"groupId":"OG005","value":"38.9","spread":null},{"groupId":"OG006","value":"51.7","spread":null},{"groupId":"OG007","value":"39.6","spread":null},{"groupId":"OG008","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":null},{"groupId":"OG001","value":"54.8","spread":null},{"groupId":"OG002","value":"58.6","spread":null},{"groupId":"OG003","value":"80.9","spread":null},{"groupId":"OG004","value":"40.0","spread":null},{"groupId":"OG005","value":"39.4","spread":null},{"groupId":"OG006","value":"55.9","spread":null},{"groupId":"OG007","value":"44.5","spread":null},{"groupId":"OG008","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"49.3","spread":null},{"groupId":"OG002","value":"61.7","spread":null},{"groupId":"OG003","value":"78.4","spread":null},{"groupId":"OG004","value":"62.5","spread":null},{"groupId":"OG005","value":"35.1","spread":null},{"groupId":"OG006","value":"65.0","spread":null},{"groupId":"OG007","value":"41.4","spread":null},{"groupId":"OG008","value":"57.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"78.3","spread":null},{"groupId":"OG002","value":"78.8","spread":null},{"groupId":"OG003","value":"87.9","spread":null},{"groupId":"OG004","value":"63.6","spread":null},{"groupId":"OG005","value":"87.4","spread":null},{"groupId":"OG006","value":"41.7","spread":null},{"groupId":"OG007","value":"79.0","spread":null},{"groupId":"OG008","value":"61.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":null},{"groupId":"OG001","value":"71.4","spread":null},{"groupId":"OG002","value":"77.6","spread":null},{"groupId":"OG003","value":"88.5","spread":null},{"groupId":"OG004","value":"50.0","spread":null},{"groupId":"OG005","value":"86.1","spread":null},{"groupId":"OG006","value":"53.8","spread":null},{"groupId":"OG007","value":"81.6","spread":null},{"groupId":"OG008","value":"75.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) Scores of 50, 90 and 100 Over Time at Weeks 52, 104, 156, 208 and 260","description":"PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null},{"groupId":"OG001","value":"98.7","spread":null},{"groupId":"OG002","value":"94.0","spread":null},{"groupId":"OG003","value":"98.8","spread":null},{"groupId":"OG004","value":"80.0","spread":null},{"groupId":"OG005","value":"86.3","spread":null},{"groupId":"OG006","value":"91.4","spread":null},{"groupId":"OG007","value":"88.3","spread":null},{"groupId":"OG008","value":"93.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":null},{"groupId":"OG001","value":"38.7","spread":null},{"groupId":"OG002","value":"50.3","spread":null},{"groupId":"OG003","value":"68.5","spread":null},{"groupId":"OG004","value":"12.7","spread":null},{"groupId":"OG005","value":"11.6","spread":null},{"groupId":"OG006","value":"19.0","spread":null},{"groupId":"OG007","value":"12.6","spread":null},{"groupId":"OG008","value":"39.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"16.0","spread":null},{"groupId":"OG002","value":"23.8","spread":null},{"groupId":"OG003","value":"43.8","spread":null},{"groupId":"OG004","value":"3.6","spread":null},{"groupId":"OG005","value":"2.1","spread":null},{"groupId":"OG006","value":"8.6","spread":null},{"groupId":"OG007","value":"3.6","spread":null},{"groupId":"OG008","value":"9.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"84.9","spread":null},{"groupId":"OG002","value":"86.5","spread":null},{"groupId":"OG003","value":"96.7","spread":null},{"groupId":"OG004","value":"80.0","spread":null},{"groupId":"OG005","value":"87.2","spread":null},{"groupId":"OG006","value":"88.2","spread":null},{"groupId":"OG007","value":"85.5","spread":null},{"groupId":"OG008","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"23.3","spread":null},{"groupId":"OG002","value":"33.8","spread":null},{"groupId":"OG003","value":"64.5","spread":null},{"groupId":"OG004","value":"16.7","spread":null},{"groupId":"OG005","value":"9.6","spread":null},{"groupId":"OG006","value":"14.7","spread":null},{"groupId":"OG007","value":"18.2","spread":null},{"groupId":"OG008","value":"26.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null},{"groupId":"OG001","value":"6.8","spread":null},{"groupId":"OG002","value":"16.5","spread":null},{"groupId":"OG003","value":"43.4","spread":null},{"groupId":"OG004","value":"10.0","spread":null},{"groupId":"OG005","value":"1.1","spread":null},{"groupId":"OG006","value":"5.9","spread":null},{"groupId":"OG007","value":"4.5","spread":null},{"groupId":"OG008","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"86.7","spread":null},{"groupId":"OG002","value":"91.3","spread":null},{"groupId":"OG003","value":"97.1","spread":null},{"groupId":"OG004","value":"93.8","spread":null},{"groupId":"OG005","value":"88.3","spread":null},{"groupId":"OG006","value":"85.0","spread":null},{"groupId":"OG007","value":"90.1","spread":null},{"groupId":"OG008","value":"90.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"17.3","spread":null},{"groupId":"OG002","value":"32.2","spread":null},{"groupId":"OG003","value":"61.9","spread":null},{"groupId":"OG004","value":"31.3","spread":null},{"groupId":"OG005","value":"10.6","spread":null},{"groupId":"OG006","value":"30.0","spread":null},{"groupId":"OG007","value":"10.8","spread":null},{"groupId":"OG008","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"8.0","spread":null},{"groupId":"OG002","value":"20.9","spread":null},{"groupId":"OG003","value":"41.7","spread":null},{"groupId":"OG004","value":"6.3","spread":null},{"groupId":"OG005","value":"4.3","spread":null},{"groupId":"OG006","value":"0.0","spread":null},{"groupId":"OG007","value":"3.6","spread":null},{"groupId":"OG008","value":"19.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.1","spread":null},{"groupId":"OG002","value":"98.1","spread":null},{"groupId":"OG003","value":"97.0","spread":null},{"groupId":"OG004","value":"72.7","spread":null},{"groupId":"OG005","value":"98.9","spread":null},{"groupId":"OG006","value":"100.0","spread":null},{"groupId":"OG007","value":"95.0","spread":null},{"groupId":"OG008","value":"95.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null},{"groupId":"OG001","value":"49.3","spread":null},{"groupId":"OG002","value":"50.0","spread":null},{"groupId":"OG003","value":"65.9","spread":null},{"groupId":"OG004","value":"27.3","spread":null},{"groupId":"OG005","value":"64.4","spread":null},{"groupId":"OG006","value":"16.7","spread":null},{"groupId":"OG007","value":"53.0","spread":null},{"groupId":"OG008","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"20.3","spread":null},{"groupId":"OG002","value":"23.1","spread":null},{"groupId":"OG003","value":"43.2","spread":null},{"groupId":"OG004","value":"9.1","spread":null},{"groupId":"OG005","value":"23.0","spread":null},{"groupId":"OG006","value":"0.0","spread":null},{"groupId":"OG007","value":"24.0","spread":null},{"groupId":"OG008","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.4","spread":null},{"groupId":"OG002","value":"97.6","spread":null},{"groupId":"OG003","value":"97.5","spread":null},{"groupId":"OG004","value":"100.0","spread":null},{"groupId":"OG005","value":"97.5","spread":null},{"groupId":"OG006","value":"100.0","spread":null},{"groupId":"OG007","value":"93.1","spread":null},{"groupId":"OG008","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"46.4","spread":null},{"groupId":"OG002","value":"48.2","spread":null},{"groupId":"OG003","value":"66.4","spread":null},{"groupId":"OG004","value":"30.0","spread":null},{"groupId":"OG005","value":"57.0","spread":null},{"groupId":"OG006","value":"7.7","spread":null},{"groupId":"OG007","value":"54.0","spread":null},{"groupId":"OG008","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","spread":null},{"groupId":"OG001","value":"17.9","spread":null},{"groupId":"OG002","value":"22.4","spread":null},{"groupId":"OG003","value":"41.0","spread":null},{"groupId":"OG004","value":"10.0","spread":null},{"groupId":"OG005","value":"29.1","spread":null},{"groupId":"OG006","value":"7.7","spread":null},{"groupId":"OG007","value":"18.4","spread":null},{"groupId":"OG008","value":"25.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 52, 104, 156, 208 and 260","description":"PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.54","spread":"21.744"},{"groupId":"OG001","value":"-81.47","spread":"16.179"},{"groupId":"OG002","value":"-82.51","spread":"19.147"},{"groupId":"OG003","value":"-91.14","spread":"13.377"},{"groupId":"OG004","value":"-65.13","spread":"23.452"},{"groupId":"OG005","value":"-67.91","spread":"21.521"},{"groupId":"OG006","value":"-75.63","spread":"16.970"},{"groupId":"OG007","value":"-69.13","spread":"18.976"},{"groupId":"OG008","value":"-79.75","spread":"17.045"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-78.13","spread":"26.278"},{"groupId":"OG001","value":"-72.47","spread":"24.099"},{"groupId":"OG002","value":"-75.02","spread":"25.168"},{"groupId":"OG003","value":"-88.48","spread":"16.273"},{"groupId":"OG004","value":"-63.17","spread":"28.596"},{"groupId":"OG005","value":"-68.40","spread":"18.057"},{"groupId":"OG006","value":"-67.62","spread":"40.039"},{"groupId":"OG007","value":"-70.98","spread":"19.720"},{"groupId":"OG008","value":"-76.10","spread":"19.342"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-90.27","spread":"11.543"},{"groupId":"OG001","value":"-71.48","spread":"19.892"},{"groupId":"OG002","value":"-78.02","spread":"19.576"},{"groupId":"OG003","value":"-88.34","spread":"15.555"},{"groupId":"OG004","value":"-78.97","spread":"16.709"},{"groupId":"OG005","value":"-68.71","spread":"18.094"},{"groupId":"OG006","value":"-77.40","spread":"18.714"},{"groupId":"OG007","value":"-69.77","spread":"18.586"},{"groupId":"OG008","value":"-76.12","spread":"20.437"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.60","spread":"12.296"},{"groupId":"OG001","value":"-85.06","spread":"14.082"},{"groupId":"OG002","value":"-85.91","spread":"13.501"},{"groupId":"OG003","value":"-90.46","spread":"14.116"},{"groupId":"OG004","value":"-72.64","spread":"24.394"},{"groupId":"OG005","value":"-89.36","spread":"12.978"},{"groupId":"OG006","value":"-74.38","spread":"13.817"},{"groupId":"OG007","value":"-85.25","spread":"17.018"},{"groupId":"OG008","value":"-79.12","spread":"16.827"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-88.75","spread":"10.928"},{"groupId":"OG001","value":"-84.10","spread":"15.012"},{"groupId":"OG002","value":"-85.68","spread":"13.867"},{"groupId":"OG003","value":"-90.06","spread":"14.639"},{"groupId":"OG004","value":"-76.20","spread":"17.418"},{"groupId":"OG005","value":"-89.40","spread":"12.763"},{"groupId":"OG006","value":"-78.13","spread":"10.197"},{"groupId":"OG007","value":"-85.48","spread":"17.116"},{"groupId":"OG008","value":"-81.47","spread":"21.335"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Investigator's Global Assessment Modified 2011 (IGA) 2011 Score of 0 or 1 Over Time at Weeks 52, 104, 156, 208 and 260","description":"The IGA mod 2011 is a static scale, i.e., it refers exclusively to the participant's disease state at the time of the assessments and does not attempt a comparison to any of the participant's previous disease states at prior visits. The score ranges from 0 (clear) to 4 (severe). The score 0 is clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 is severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"50.7","spread":null},{"groupId":"OG002","value":"55.0","spread":null},{"groupId":"OG003","value":"69.1","spread":null},{"groupId":"OG004","value":"20.0","spread":null},{"groupId":"OG005","value":"20.0","spread":null},{"groupId":"OG006","value":"28.3","spread":null},{"groupId":"OG007","value":"19.8","spread":null},{"groupId":"OG008","value":"42.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"30.1","spread":null},{"groupId":"OG002","value":"39.8","spread":null},{"groupId":"OG003","value":"66.4","spread":null},{"groupId":"OG004","value":"20.0","spread":null},{"groupId":"OG005","value":"16.0","spread":null},{"groupId":"OG006","value":"17.6","spread":null},{"groupId":"OG007","value":"17.3","spread":null},{"groupId":"OG008","value":"23.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null},{"groupId":"OG001","value":"21.3","spread":null},{"groupId":"OG002","value":"35.7","spread":null},{"groupId":"OG003","value":"56.8","spread":null},{"groupId":"OG004","value":"37.5","spread":null},{"groupId":"OG005","value":"14.9","spread":null},{"groupId":"OG006","value":"25.0","spread":null},{"groupId":"OG007","value":"15.3","spread":null},{"groupId":"OG008","value":"28.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null},{"groupId":"OG001","value":"47.1","spread":null},{"groupId":"OG002","value":"50.5","spread":null},{"groupId":"OG003","value":"62.1","spread":null},{"groupId":"OG004","value":"41.7","spread":null},{"groupId":"OG005","value":"63.2","spread":null},{"groupId":"OG006","value":"8.3","spread":null},{"groupId":"OG007","value":"52.0","spread":null},{"groupId":"OG008","value":"23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null},{"groupId":"OG001","value":"48.2","spread":null},{"groupId":"OG002","value":"50.6","spread":null},{"groupId":"OG003","value":"65.0","spread":null},{"groupId":"OG004","value":"40.0","spread":null},{"groupId":"OG005","value":"58.2","spread":null},{"groupId":"OG006","value":"30.8","spread":null},{"groupId":"OG007","value":"54.0","spread":null},{"groupId":"OG008","value":"37.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Dermatology Life Quality Index (DLQI©) Response at Weeks 52, 104, 156, 208 and 260","description":"The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). \"Not relevant\" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-77.3","spread":null},{"groupId":"OG001","value":"-85.7","spread":null},{"groupId":"OG002","value":"-81.8","spread":null},{"groupId":"OG003","value":"-93.3","spread":null},{"groupId":"OG004","value":"-65.0","spread":null},{"groupId":"OG005","value":"-68.2","spread":null},{"groupId":"OG006","value":"-66.7","spread":null},{"groupId":"OG007","value":"-72.8","spread":null},{"groupId":"OG008","value":"-79.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-70.8","spread":null},{"groupId":"OG001","value":"-73.8","spread":null},{"groupId":"OG002","value":"-73.3","spread":null},{"groupId":"OG003","value":"-87.5","spread":null},{"groupId":"OG004","value":"-71.9","spread":null},{"groupId":"OG005","value":"-63.6","spread":null},{"groupId":"OG006","value":"-68.8","spread":null},{"groupId":"OG007","value":"-74.9","spread":null},{"groupId":"OG008","value":"-77.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-89.3","spread":null},{"groupId":"OG001","value":"-67.9","spread":null},{"groupId":"OG002","value":"-75.0","spread":null},{"groupId":"OG003","value":"-91.7","spread":null},{"groupId":"OG004","value":"-79.6","spread":null},{"groupId":"OG005","value":"-60.6","spread":null},{"groupId":"OG006","value":"-73.9","spread":null},{"groupId":"OG007","value":"-66.7","spread":null},{"groupId":"OG008","value":"-80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.5","spread":null},{"groupId":"OG001","value":"-81.3","spread":null},{"groupId":"OG002","value":"-83.3","spread":null},{"groupId":"OG003","value":"-92.1","spread":null},{"groupId":"OG004","value":"-75.0","spread":null},{"groupId":"OG005","value":"-85.7","spread":null},{"groupId":"OG006","value":"-74.1","spread":null},{"groupId":"OG007","value":"-84.6","spread":null},{"groupId":"OG008","value":"-81.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-90.9","spread":null},{"groupId":"OG001","value":"-84.8","spread":null},{"groupId":"OG002","value":"-86.1","spread":null},{"groupId":"OG003","value":"-92.3","spread":null},{"groupId":"OG004","value":"-75.0","spread":null},{"groupId":"OG005","value":"-82.3","spread":null},{"groupId":"OG006","value":"-63.9","spread":null},{"groupId":"OG007","value":"-83.3","spread":null},{"groupId":"OG008","value":"-80.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Dermatology Life Quality Index (DLQI©) Response (DLQI 0 or 1) Over Time at Weeks 52, 104, 156, 208 and 260","description":"The DLQI is a quality of life measure used in the psoriatic The 10-item questionnaire has a score range of 0 (best) to 30 (worst) with higher scores indicating poor quality of life. The instrument contains six functional scales (i.e., symptoms and feeling, daily activities, leisure, work and school, personal relationships, treatment). Each item has 4 response categories, ranging from 0 (not at all) to 3 (very much). \"Not relevant\" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.7","spread":null},{"groupId":"OG001","value":"57.3","spread":null},{"groupId":"OG002","value":"58.6","spread":null},{"groupId":"OG003","value":"72.7","spread":null},{"groupId":"OG004","value":"32.7","spread":null},{"groupId":"OG005","value":"34.7","spread":null},{"groupId":"OG006","value":"28.3","spread":null},{"groupId":"OG007","value":"41.4","spread":null},{"groupId":"OG008","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null},{"groupId":"OG001","value":"47.2","spread":null},{"groupId":"OG002","value":"50.7","spread":null},{"groupId":"OG003","value":"64.7","spread":null},{"groupId":"OG004","value":"41.2","spread":null},{"groupId":"OG005","value":"33.0","spread":null},{"groupId":"OG006","value":"32.5","spread":null},{"groupId":"OG007","value":"41.5","spread":null},{"groupId":"OG008","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"37.3","spread":null},{"groupId":"OG002","value":"47.4","spread":null},{"groupId":"OG003","value":"67.4","spread":null},{"groupId":"OG004","value":"43.8","spread":null},{"groupId":"OG005","value":"35.5","spread":null},{"groupId":"OG006","value":"38.1","spread":null},{"groupId":"OG007","value":"38.5","spread":null},{"groupId":"OG008","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"52.9","spread":null},{"groupId":"OG002","value":"56.1","spread":null},{"groupId":"OG003","value":"70.5","spread":null},{"groupId":"OG004","value":"30.8","spread":null},{"groupId":"OG005","value":"62.5","spread":null},{"groupId":"OG006","value":"42.9","spread":null},{"groupId":"OG007","value":"59.0","spread":null},{"groupId":"OG008","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"54.7","spread":null},{"groupId":"OG003","value":"65.5","spread":null},{"groupId":"OG004","value":"60.0","spread":null},{"groupId":"OG005","value":"55.7","spread":null},{"groupId":"OG006","value":"15.6","spread":null},{"groupId":"OG007","value":"56.3","spread":null},{"groupId":"OG008","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D©) Score and Percent Change From Baseline at Weeks 52, 104 and 156","description":"ED-5Q: Participant rated questionnaire to assess health related quality of life in terms of a single utility score. Five domains are assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each with three possible score: 1 indicates no problems, better state of health; 3 indicates worst state of health (example \"confined to bed\") A visual analog scale (VAS) assesses the health status from 0 (worst possible health state) to 100 (best possible health state)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":"137.47"},{"groupId":"OG001","value":"57.0","spread":"137.79"},{"groupId":"OG002","value":"63.0","spread":"137.30"},{"groupId":"OG003","value":"115.8","spread":"666.41"},{"groupId":"OG004","value":"40.2","spread":"94.91"},{"groupId":"OG005","value":"76.9","spread":"222.97"},{"groupId":"OG006","value":"41.3","spread":"140.42"},{"groupId":"OG007","value":"98.8","spread":"359.93"},{"groupId":"OG008","value":"60.9","spread":"74.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","spread":"122.96"},{"groupId":"OG001","value":"62.4","spread":"156.21"},{"groupId":"OG002","value":"60.6","spread":"140.91"},{"groupId":"OG003","value":"118.5","spread":"689.52"},{"groupId":"OG004","value":"29.5","spread":"70.63"},{"groupId":"OG005","value":"152.9","spread":"902.21"},{"groupId":"OG006","value":"46.7","spread":"142.85"},{"groupId":"OG007","value":"77.2","spread":"150.86"},{"groupId":"OG008","value":"54.3","spread":"84.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":"114.81"},{"groupId":"OG001","value":"52.1","spread":"115.04"},{"groupId":"OG002","value":"55.2","spread":"114.53"},{"groupId":"OG003","value":"125.3","spread":"677.23"},{"groupId":"OG004","value":"45.1","spread":"102.64"},{"groupId":"OG005","value":"140.3","spread":"778.86"},{"groupId":"OG006","value":"13.7","spread":"25.16"},{"groupId":"OG007","value":"109.5","spread":"373.51"},{"groupId":"OG008","value":"68.1","spread":"96.22"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Anti-drug Antibodies (ADA)","description":"The development of anti-secunimubab anti-bodies will decrease a participant's ability to respond to secukinumab treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"4","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"4","spread":null},{"groupId":"OG007","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Experiencing a Relapse","description":"Relapse is defined as greater than 50% loss of the maximal PASI improvement from baseline.\n\nPASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"19.6","spread":null},{"groupId":"OG003","value":"61.8","spread":null},{"groupId":"OG004","value":"52.6","spread":null},{"groupId":"OG005","value":"43.3","spread":null},{"groupId":"OG006","value":"56.3","spread":null},{"groupId":"OG007","value":"36.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Experiencing a Rebound","description":"Rebound of disease is defined as a worsening of PASI of \\> 125% of the value at baseline (core study), or new pustular, erythrodermic or more inflammatory psoriasis occurring within 8 weeks of stopping therapy (i.e., if this definition was fulfilled at more than 8 weeks after last study treatment administration, this was defined as rebound like event).\n\nPASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"5.8","spread":null},{"groupId":"OG002","value":"5.0","spread":null},{"groupId":"OG003","value":"9.4","spread":null},{"groupId":"OG004","value":"1.1","spread":null},{"groupId":"OG005","value":"6.9","spread":null},{"groupId":"OG006","value":"10.6","spread":null},{"groupId":"OG007","value":"13.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":132},"commonTop":["NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","ARTHRALGIA","HYPERTENSION","BACK PAIN"]}}}